Business
Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors
Strategic leadership to drive next phase of growth for the company LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in
About this update from Agenus Inc.
[{"type":"text","content":"\nStrategic leadership to drive next phase of growth for the company\n\n\n LEXINGTON, Mass.--(BUSINESS WIRE)--\nAgenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, is pleased to announce the appointment of Dr. Jennifer Buell to its Board of Directors, on June 11, 2024, effective immediately. Dr. Buell will maintain her active and ongoing role as the President and CEO of MiNK Therapeutics, in addition to her responsibilities as Chairman of the Executive Council at Agenus. Her continued leadership at MiNK ensures a seamless integration of strategic insights across both organizations, enhancing our collaborative efforts to innovate and deliver breakthrough cancer therapies.\n\n\n\"Dr. Buell’s appointment is a testament to her unparalleled leadership and her profound impact on Agenus,\" said Dr. Garo Armen, Chairman and CEO of Agenus. \"Her strategic vision and operational expertise have been instrumental in transforming Agenus from a single-product company into a global, fully integrated biotech leader. We are confident that her guidance will be equally influential in her expanded role as a board member.”\n\n\nDr. Buell brings to the board over 27 years of extensive experience in the biopharmaceutical industry, encompassing leadership roles in research and development, clinical operations, and commercial strategy. Her expertise in advancing discovery candidates through to clinical development and commercialization will be invaluable to Agenus as the company continues to expand its innovative pipeline.\n\n\nDuring her tenure as President and COO at Agenus, Dr. Buell spearheaded initiatives that transformed the company into a global, fully integrated biotech leader with a robust immuno-oncology portfolio. Her leadership was pivotal in expanding strategic partnerships, enhancing operational capabilities, and establishing Agenus as an industry visionary.\n\n\nBefore her time at Agenus, Dr. Buell held key positions at Bristol-Myers Squibb and the Harvard Clinical Research Institute (Baim), where she was deeply involved in the development and operational strategies of numerous clinical programs, both industry and government sponsored. Dr. Buell earned her Ph.D. in Cellular, Biochemical, and Molecular Biochemistry and an M.S. in Biostatistics from Tufts University, further gro...